# Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression

> **NCT05154383** · PHASE4 · COMPLETED · sponsor: **Centre Hospitalier Annecy Genevois** · enrollment: 60 (actual)

## Conditions studied

- Vaccine Reaction

## Interventions

- **BIOLOGICAL:** Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)
- **BIOLOGICAL:** Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT05154383
- **Lead sponsor:** Centre Hospitalier Annecy Genevois
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-08-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05154383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05154383, "Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05154383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*